Pathological and morphometric assessment of testicular parameters in patients with metastatic prostate cancer following treatment with either the antiandrogen Casodex (ZM176,334) or bilateral orchidectomy
- 1 January 1994
- journal article
- clinical trial
- Published by Springer Nature in Urological Research
- Vol. 22 (3) , 191-195
- https://doi.org/10.1007/bf00571849
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Casodex: A pure non-steroidal anti-androgen used as monotherapy in advanced prostate cancerThe Prostate, 1992
- Endocrine Therapy for Prostate CancerEndocrinology and Metabolism Clinics of North America, 1991
- A possible explanation for the peripheral selectivity of a novel non-steroidal pure antiandrogen, Casodex (ICI 176,334)British Journal of Cancer, 1989
- Casodex (ICI 176,334), A New, Non-Steroidal Anti-Androgen. Early Clinical ResultsHormone Research, 1989
- “Casodex”(ICI 176,334) – A New, Pure, Peripherally-Selective Anti-Androgen: Preclinical StudiesHormone Research, 1989
- Total androgen suppression: are there any advantages? The use of combined therapy in the treatment of advanced prostate adenocarcinoma.1988
- ICI 176,334: A NOVEL NON–STEROIDAL, PERIPHERALLY SELECTIVE ANTIANDROGENJournal of Endocrinology, 1987
- Design of Antiandrogens and Their Mechanisms of Action: A Case Study (Anandron)Hormone Research, 1987
- The different mechanisms for suppression of pituitary and testicular function.1986
- A new approach in the hormonal treatment of prostate cancer: complete instead of partial blockade of androgensInternational Journal of Andrology, 1984